GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CEN Biotech Inc (OTCPK:CENBF) » Definitions » Net Cash per Share

CEN Biotech (CEN Biotech) Net Cash per Share : $-0.15 (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is CEN Biotech Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). CEN Biotech's Net Cash per Share for the quarter that ended in Mar. 2023 was $-0.15.

The historical rank and industry rank for CEN Biotech's Net Cash per Share or its related term are showing as below:

CENBF's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.13
* Ranked among companies with meaningful Price-to-Net-Cash only.

CEN Biotech Net Cash per Share Historical Data

The historical data trend for CEN Biotech's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEN Biotech Net Cash per Share Chart

CEN Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only -1.12 -1.22 -0.59 -0.18 -0.16

CEN Biotech Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.16 -0.15 -0.16 -0.15

Competitive Comparison of CEN Biotech's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, CEN Biotech's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEN Biotech's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CEN Biotech's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where CEN Biotech's Price-to-Net-Cash falls into.



CEN Biotech Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

CEN Biotech's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.084-10.151-0)/64.7411
=-0.16

CEN Biotech's Net Cash per Share for the quarter that ended in Mar. 2023 is calculated as

Net Cash per Share (Q: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.136-10.118-0)/65.2561
=-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CEN Biotech  (OTCPK:CENBF) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


CEN Biotech Net Cash per Share Related Terms

Thank you for viewing the detailed overview of CEN Biotech's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CEN Biotech (CEN Biotech) Business Description

Traded in Other Exchanges
N/A
Address
3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9
Website
CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.
Executives
Lawrence Lehoux director, officer: Chief Technology Officer 11879 SOLOMAN ST, WINDSOR A6 N8P 1P1
Jeffery Allen Thomas director 23772 WEST ROAD #152, BROWNSTOWN TOWNSHIP MI 48183
Rick Leigh Purdy director 9 ELAINE STREET, ST. ALBERT A0 T8N7R6
Usamakh Saadikh director 3 DRUDBGY NARODOV SQUARE, KYIV 2H 04210
Joseph A. Byrne director, officer: Chief Executive Officer 6 CAMERON SIDE ROAD EAST, ESSEX A6 N8M 2X5
Alex Tarrabain director 18908 89 AVENUE, EDMONTON A0 T5T 6B7
Donald Strilchuck director 352 RIDEAU PL, TECUMSEH A6 N8N 3N9
Richard Boswell director, 10 percent owner, officer: CFO Senior Executive VP 2408 EASTERN AVE., ROCHESTER HILLS MI 48307
Ameen Ferris director 30 AYRSHIRE COURT, BRAMPTON A6 L6Z 0G6
Brian Payne director, officer: Vice President 1027 HUNTINGTON BLVD, BELLE RIVER A6 N0R 1A0
Aubrey De Lavenu Harold Andre director APT 627 VALE DO LOBO, ALMANCIL S1 8135-034
Bahige B. Chaaban director, 10 percent owner, officer: Chief Executive Officer 888 OLD TECUMSAH RD., BELLE RIVER A6 N0R 1A0

CEN Biotech (CEN Biotech) Headlines